Artia Global Partners LP Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)

Artia Global Partners LP purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 162,976 shares of the company’s stock, valued at approximately $8,726,000. Janux Therapeutics comprises 3.1% of Artia Global Partners LP’s holdings, making the stock its 13th largest holding. Artia Global Partners LP owned 0.31% of Janux Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company’s stock valued at $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after purchasing an additional 986,750 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Janux Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company’s stock worth $114,379,000 after purchasing an additional 288,402 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in shares of Janux Therapeutics by 80.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company’s stock worth $67,878,000 after purchasing an additional 564,322 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Janux Therapeutics by 596.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock valued at $59,429,000 after buying an additional 950,557 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,464,170. This represents a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the transaction, the director now directly owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 10,002 shares of company stock worth $348,203. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Trading Down 3.2 %

Janux Therapeutics stock opened at $31.05 on Friday. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -26.54 and a beta of 3.27. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The stock’s 50 day moving average is $30.08 and its 200-day moving average is $43.11.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JANX has been the topic of several analyst reports. Wedbush reaffirmed an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.